Vinorelbine and venous irritation: optimal parenteral administration
Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush ≥75-124 mL of intraven...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2005-06, Vol.11 (2), p.79-81 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 81 |
|---|---|
| container_issue | 2 |
| container_start_page | 79 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 11 |
| creator | de Lemos, Mário L |
| description | Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush ≥75-124 mL of intravenous fluid after vinorelbine infusion. In travenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min. |
| doi_str_mv | 10.1191/1078155205jp146oa |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_221216681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_1078155205jp146oa</sage_id><sourcerecordid>869095281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323a-90d8478446d35b05eec48bf8f4cf4d9028a2fbce414c098d81e6a7811f7c88213</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMo7rr6A7xI8d41k6Zp6k3WT1jwouKtpPmQLLtJTVrBf2_qLuxBPM0L88w7My9C54DnADVcAa44lCXB5aoDyrw4QFOgVZXjmrwfJp36-QhM0EmMK4wxrwg_RhNglGGG-RTdvlnng1631ulMOJV9aeeHmNkQbC9669115rvebsQ660TQrtchSaE21tnYh1_kFB0ZsY76bFdn6PX-7mXxmC-fH54WN8tcFqQQeY0VpxWnlKmibHGptaS8NdxQaaiqMeGCmFZqClTimisOmon0IZhKck6gmKHLrW8X_OegY9-s_BBcWtkQAgQY4yMEW0gGH2PQpulCOj98N4CbMbbmT2xp5mJnPLQbrfYTu5wSMN8CUXzo_db_HX8AILl3Rg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221216681</pqid></control><display><type>article</type><title>Vinorelbine and venous irritation: optimal parenteral administration</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>de Lemos, Mário L</creator><creatorcontrib>de Lemos, Mário L</creatorcontrib><description>Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush ≥75-124 mL of intravenous fluid after vinorelbine infusion. In travenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1191/1078155205jp146oa</identifier><identifier>PMID: 16460608</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - adverse effects ; Antineoplastic Agents, Phytogenic - therapeutic use ; Clinical Trials, Phase III as Topic ; Humans ; Infusions, Intravenous - adverse effects ; Infusions, Intravenous - methods ; Phlebitis - chemically induced ; Randomized Controlled Trials as Topic ; Veins - injuries ; Vinblastine - administration & dosage ; Vinblastine - adverse effects ; Vinblastine - analogs & derivatives ; Vinblastine - therapeutic use</subject><ispartof>Journal of oncology pharmacy practice, 2005-06, Vol.11 (2), p.79-81</ispartof><rights>2005 Arnold</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323a-90d8478446d35b05eec48bf8f4cf4d9028a2fbce414c098d81e6a7811f7c88213</citedby><cites>FETCH-LOGICAL-c323a-90d8478446d35b05eec48bf8f4cf4d9028a2fbce414c098d81e6a7811f7c88213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/1078155205jp146oa$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/1078155205jp146oa$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21817,27922,27923,43619,43620</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16460608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Lemos, Mário L</creatorcontrib><title>Vinorelbine and venous irritation: optimal parenteral administration</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush ≥75-124 mL of intravenous fluid after vinorelbine infusion. In travenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min.</description><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Agents, Phytogenic - adverse effects</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Humans</subject><subject>Infusions, Intravenous - adverse effects</subject><subject>Infusions, Intravenous - methods</subject><subject>Phlebitis - chemically induced</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Veins - injuries</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - adverse effects</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vinblastine - therapeutic use</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1LxDAQhoMo7rr6A7xI8d41k6Zp6k3WT1jwouKtpPmQLLtJTVrBf2_qLuxBPM0L88w7My9C54DnADVcAa44lCXB5aoDyrw4QFOgVZXjmrwfJp36-QhM0EmMK4wxrwg_RhNglGGG-RTdvlnng1631ulMOJV9aeeHmNkQbC9669115rvebsQ660TQrtchSaE21tnYh1_kFB0ZsY76bFdn6PX-7mXxmC-fH54WN8tcFqQQeY0VpxWnlKmibHGptaS8NdxQaaiqMeGCmFZqClTimisOmon0IZhKck6gmKHLrW8X_OegY9-s_BBcWtkQAgQY4yMEW0gGH2PQpulCOj98N4CbMbbmT2xp5mJnPLQbrfYTu5wSMN8CUXzo_db_HX8AILl3Rg</recordid><startdate>200506</startdate><enddate>200506</enddate><creator>de Lemos, Mário L</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>200506</creationdate><title>Vinorelbine and venous irritation: optimal parenteral administration</title><author>de Lemos, Mário L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323a-90d8478446d35b05eec48bf8f4cf4d9028a2fbce414c098d81e6a7811f7c88213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Agents, Phytogenic - adverse effects</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Humans</topic><topic>Infusions, Intravenous - adverse effects</topic><topic>Infusions, Intravenous - methods</topic><topic>Phlebitis - chemically induced</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Veins - injuries</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - adverse effects</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vinblastine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Lemos, Mário L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Lemos, Mário L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vinorelbine and venous irritation: optimal parenteral administration</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2005-06</date><risdate>2005</risdate><volume>11</volume><issue>2</issue><spage>79</spage><epage>81</epage><pages>79-81</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush ≥75-124 mL of intravenous fluid after vinorelbine infusion. In travenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>16460608</pmid><doi>10.1191/1078155205jp146oa</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2005-06, Vol.11 (2), p.79-81 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_journals_221216681 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Clinical Trials, Phase III as Topic Humans Infusions, Intravenous - adverse effects Infusions, Intravenous - methods Phlebitis - chemically induced Randomized Controlled Trials as Topic Veins - injuries Vinblastine - administration & dosage Vinblastine - adverse effects Vinblastine - analogs & derivatives Vinblastine - therapeutic use |
| title | Vinorelbine and venous irritation: optimal parenteral administration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vinorelbine%20and%20venous%20irritation:%20optimal%20parenteral%20administration&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=de%20Lemos,%20M%C3%A1rio%20L&rft.date=2005-06&rft.volume=11&rft.issue=2&rft.spage=79&rft.epage=81&rft.pages=79-81&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1191/1078155205jp146oa&rft_dat=%3Cproquest_cross%3E869095281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221216681&rft_id=info:pmid/16460608&rft_sage_id=10.1191_1078155205jp146oa&rfr_iscdi=true |